May 14, 2020

Pegoretti et al. published in Oxidative Medicine and Cellular Longevity

Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development


Valentina Pegoretti, Kathryn A. Swanson, John R. Bethea, Lesley Probert, Ulrich L. M. Eisel and Roman Fischer

 

Abstract

CNS inflammation is a major driver of MS pathology. Differential immune responses, including the adaptive and the innate immune system, are observed at various stages of MS and drive disease development and progression. Next to these immune-mediated mechanisms, other mediators contribute to MS pathology. These include immune-independent cell death of oligodendrocytes and neurons as well as oxidative stress-induced tissue damage. In particular, the complex influence of oxidative stress on inflammation and vice versa makes therapeutic interference complex. All approved MS therapeutics work by modulating the autoimmune response. However, despite substantial developments in the treatment of the relapsing-remitting form of MS, approved therapies for the progressive forms of MS as well as for MS-associated concomitants are limited and much needed. Here, we summarize the contribution of inflammation and oxidative stress to MS pathology and discuss consequences for MS therapy development.

To the top of the page